G
Giovanni Barosi
Researcher at University of Pavia
Publications - 352
Citations - 21433
Giovanni Barosi is an academic researcher from University of Pavia. The author has contributed to research in topics: Myelofibrosis & Essential thrombocythemia. The author has an hindex of 69, co-authored 334 publications receiving 19225 citations.
Papers
More filters
Journal ArticleDOI
Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis
Massimo Primignani,Giovanni Barosi,Gaetano Bergamaschi,Umberto Gianelli,Federica Fabris,R. Reati,Alessandra Dell'Era,Paolo Bucciarelli,Pier Mannuccio Mannucci +8 more
TL;DR: JAK2 V617F is a very reliable and noninvasive molecular marker for CMPD and should be used as a first test for diagnosis and is the major cause of primary EHPVO or BCS.
Journal ArticleDOI
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation
Tiziano Barbui,Giovanni Barosi,Alberto Grossi,Luigi Gugliotta,Lucio N. Liberato,Monia Marchetti,M. Gabriella Mazzucconi,Francesco Rodeghiero,Sante Tura +8 more
TL;DR: The Italian Society of Hematology (SIE) and the two affiliated Societies (SIES and GITMO) commissioned a project to develop guidelines for the therapy of essential thrombocythemia (ET) using evidence-based knowledge and consensus formation techniques as mentioned in this paper.
Journal ArticleDOI
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Paola Guglielmelli,Terra L. Lasho,Giada Rotunno,Joannah Score,Carmela Mannarelli,Alessandro Pancrazzi,Flavia Biamonte,Animesh Pardanani,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Tiziana Fanelli,Daniela Pietra,Elisa Rumi,Christy Finke,Naseema Gangat,Rhett P. Ketterling,Ryan A. Knudson,C A Hanson,Alberto Bosi,Arturo Pereira,Rossella Manfredini,Francisco Cervantes,Giovanni Barosi,Marie Cazzola,Nicholas C.P. Cross,Alessandro M. Vannucchi,Ayalew Tefferi +27 more
TL;DR: It is concluded that the ‘number’ of prognostically detrimental mutations provides added value in the combined molecular and clinical progNostication of PMF.
Journal ArticleDOI
EZH2 mutational status predicts poor survival in myelofibrosis
Paola Guglielmelli,Flavia Biamonte,Joannah Score,Joannah Score,Claire Hidalgo-Curtis,Claire Hidalgo-Curtis,Francisco Cervantes,Margherita Maffioli,Tiziana Fanelli,Thomas Ernst,Nils Winkelman,Amy V. Jones,Amy V. Jones,Katerina Zoi,Andreas Reiter,Andrew S Duncombe,Laura Villani,Alberto Bosi,Giovanni Barosi,Nicholas C.P. Cross,Nicholas C.P. Cross,Alessandro M. Vannucchi +21 more
TL;DR: EZH2 mutations are independently associated with shorter survival in patients with PMF and in multivariate analysis, survival of PMF patients was predicted by IPSS high-risk category, a < 25% JAK2V617F allele burden, and EZh2 mutation status.
Journal ArticleDOI
JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.
Giovanni Barosi,Gaetano Bergamaschi,Monia Marchetti,Alessandro M. Vannucchi,Paola Guglielmelli,Elisabetta Antonioli,Margherita Massa,Vittorio Rosti,Rita Campanelli,Laura Villani,Gianluca Viarengo,Elisabetta Gattoni,Giancarla Gerli,Giorgina Specchia,Carmine Tinelli,Alessandro Rambaldi,Tiziano Barbui +16 more
TL;DR: The JAK2 V617F genotype should be considered in any future risk stratification of patients with PMF and independently predicted the evolution toward large splenomegaly, need of splenectomy, and leukemic transformation.